A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity
Status:
RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of WVE-007 when administered subcutaneously (SC) as single ascending doses in adults who are affected by overweight or obesity.